Why transplant recipients must think differently from other CKD patients
Quick answer
Transplant recipients take lifelong immunosuppression to prevent rejection, which makes any cell therapy unusually complex: it can disturb immune balance and drug levels. Nobody in this group should decide alone — the decision belongs with the transplant team.
Many immunosuppressants have a narrow therapeutic window. Anything that alters hepatic enzymes or systemic inflammation can push levels too high or too low, risking drug toxicity or graft rejection.
Conversely, MSCs are studied in transplantation precisely for immunomodulation that might reduce rejection — but strictly inside controlled research protocols, not as a commercial service.
Recipients should focus on precise dosing times, attending drug-level and renal monitoring, preventing infection, and avoiding supplements that interfere with drug metabolism, such as enzyme-inducing herbs.
It remains a research question with no confirmed answer in routine practice.
Return to the transplant team immediately to identify rejection, infection or inappropriate drug levels.
Yes, every product and procedure, because some materially change drug levels.
Yes when stable and with enough medication; always carry an English summary and drug list.
Yes as advised by the team, avoiding live vaccines while immunosuppressed.
5 points • reviewed 2026-09-02
Reviewed and last updated: 2026-09-02
5 sources • every claim is traceable
https://www.ehlbio.co.kr
https://www.mfds.go.kr/eng/index.do
https://www.mohw.go.kr/eng/
https://pubmed.ncbi.nlm.nih.gov/
https://www.medicalkorea.or.kr/
Last updated: 2026-09-02 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.
Back to categories